AAPL313.39+2.73 (+0.88%) ▲|ABBV252.74-1.91 (-0.75%) ▼|ABT95.18-0.66 (-0.69%) ▼|ACN137.19-4.95 (-3.48%) ▼|ADBE220.94-0.60 (-0.27%) ▼|AMAT570.50+16.00 (+2.89%) ▲|AMD517.41+1.30 (+0.25%) ▲|AMGN367.99-0.11 (-0.03%) ▼|AMT165.04-0.21 (-0.13%) ▼|AMZN243.62-2.36 (-0.96%) ▼|AVGO388.69+17.91 (+4.83%) ▲|AXP336.39-13.19 (-3.77%) ▼|BA224.95-6.73 (-2.90%) ▼|BAC58.30-1.56 (-2.61%) ▼|BKNG174.29-7.66 (-4.21%) ▼|BLK990.34-19.09 (-1.89%) ▼|BMY57.54-0.43 (-0.74%) ▼|BNY150.14-2.77 (-1.81%) ▼|BRK-B494.79-9.21 (-1.83%) ▼|C137.39-3.38 (-2.40%) ▼|CAT948.08+7.96 (+0.85%) ▲|CL93.04-1.99 (-2.09%) ▼|CMCSA23.19-0.22 (-0.94%) ▼|COF191.95-10.94 (-5.39%) ▼|COP110.72+2.28 (+2.10%) ▲|COST953.13+5.63 (+0.59%) ▲|CRM166.58-2.94 (-1.73%) ▼|CSCO113.82+2.03 (+1.82%) ▲|CVS104.47+0.14 (+0.13%) ▲|CVX175.97+1.96 (+1.13%) ▲|DE596.74-6.87 (-1.14%) ▼|DHR190.77-3.42 (-1.76%) ▼|DIS96.70-0.78 (-0.80%) ▼|DUK126.79-1.43 (-1.12%) ▼|EMR136.48-1.43 (-1.04%) ▼|FDX309.76-3.12 (-1.00%) ▼|GD374.31-0.33 (-0.09%) ▼|GE356.03-10.95 (-2.98%) ▼|GEV1,070.99-6.09 (-0.57%) ▼|GILD135.82-0.54 (-0.40%) ▼|GM76.24+0.21 (+0.28%) ▲|GOOG358.71-4.91 (-1.35%) ▼|GOOGL361.92-5.11 (-1.39%) ▼|GS1,029.64-13.34 (-1.28%) ▼|HD336.21-9.00 (-2.61%) ▼|HON220.36-4.69 (-2.08%) ▼|IBM302.05-4.08 (-1.33%) ▼|INTC110.24-0.15 (-0.14%) ▼|INTU272.10-9.07 (-3.23%) ▼|ISRG415.10-12.20 (-2.86%) ▼|JNJ263.40-3.84 (-1.44%) ▼|JPM330.62-8.60 (-2.54%) ▼|KO83.40-0.65 (-0.77%) ▼|LIN527.67-10.56 (-1.96%) ▼|LLY1,215.83-19.73 (-1.60%) ▼|LMT527.96-7.42 (-1.39%) ▼|LOW212.85-8.05 (-3.64%) ▼|LRCX333.15+7.02 (+2.15%) ▲|MA519.86-11.76 (-2.21%) ▼|MCD278.25-3.96 (-1.40%) ▼|MDLZ59.48-0.74 (-1.23%) ▼|MDT82.01-1.82 (-2.17%) ▼|META603.12-12.46 (-2.02%) ▼|MMM154.70-3.31 (-2.09%) ▼|MO72.81-0.15 (-0.21%) ▼|MRK125.99-2.87 (-2.23%) ▼|MS218.07-3.97 (-1.79%) ▼|MSFT383.34-5.50 (-1.41%) ▼|MU948.80+10.42 (+1.11%) ▲|NEE87.44-1.03 (-1.16%) ▼|NFLX75.59-0.59 (-0.77%) ▼|NKE42.89-0.32 (-0.74%) ▼|NOW107.78-2.95 (-2.66%) ▼|NVDA204.12+7.19 (+3.65%) ▲|ORCL140.49-1.11 (-0.78%) ▼|PEP142.51-2.47 (-1.70%) ▼|PFE24.05-0.02 (-0.08%) ▼|PG148.40-4.35 (-2.85%) ▼|PLTR132.22-2.15 (-1.60%) ▼|PM187.07-0.72 (-0.38%) ▼|QCOM186.56+3.59 (+1.96%) ▲|RTX194.91-5.94 (-2.96%) ▼|SBUX103.87+0.26 (+0.25%) ▲|SCHW101.70-0.23 (-0.23%) ▼|SO96.38-0.91 (-0.94%) ▼|SPG219.09-8.10 (-3.57%) ▼|T21.12+0.03 (+0.14%) ▲|TMO510.13-6.49 (-1.26%) ▼|TMUS180.14-4.59 (-2.48%) ▼|TSLA394.06-8.84 (-2.19%) ▼|TXN301.32+8.02 (+2.73%) ▲|UBER73.60-0.73 (-0.98%) ▼|UNH425.60-2.59 (-0.60%) ▼|UNP280.94-2.18 (-0.77%) ▼|UPS109.94-2.02 (-1.80%) ▼|USB61.00-1.89 (-3.01%) ▼|V347.53-4.67 (-1.33%) ▼|VZ42.45-0.14 (-0.33%) ▼|WFC85.56-1.62 (-1.86%) ▼|WMT113.10+1.56 (+1.40%) ▲|XOM141.13-0.56 (-0.40%) ▼|AAPL313.39+2.73 (+0.88%) ▲|ABBV252.74-1.91 (-0.75%) ▼|ABT95.18-0.66 (-0.69%) ▼|ACN137.19-4.95 (-3.48%) ▼|ADBE220.94-0.60 (-0.27%) ▼|AMAT570.50+16.00 (+2.89%) ▲|AMD517.41+1.30 (+0.25%) ▲|AMGN367.99-0.11 (-0.03%) ▼|AMT165.04-0.21 (-0.13%) ▼|AMZN243.62-2.36 (-0.96%) ▼|AVGO388.69+17.91 (+4.83%) ▲|AXP336.39-13.19 (-3.77%) ▼|BA224.95-6.73 (-2.90%) ▼|BAC58.30-1.56 (-2.61%) ▼|BKNG174.29-7.66 (-4.21%) ▼|BLK990.34-19.09 (-1.89%) ▼|BMY57.54-0.43 (-0.74%) ▼|BNY150.14-2.77 (-1.81%) ▼|BRK-B494.79-9.21 (-1.83%) ▼|C137.39-3.38 (-2.40%) ▼|CAT948.08+7.96 (+0.85%) ▲|CL93.04-1.99 (-2.09%) ▼|CMCSA23.19-0.22 (-0.94%) ▼|COF191.95-10.94 (-5.39%) ▼|COP110.72+2.28 (+2.10%) ▲|COST953.13+5.63 (+0.59%) ▲|CRM166.58-2.94 (-1.73%) ▼|CSCO113.82+2.03 (+1.82%) ▲|CVS104.47+0.14 (+0.13%) ▲|CVX175.97+1.96 (+1.13%) ▲|DE596.74-6.87 (-1.14%) ▼|DHR190.77-3.42 (-1.76%) ▼|DIS96.70-0.78 (-0.80%) ▼|DUK126.79-1.43 (-1.12%) ▼|EMR136.48-1.43 (-1.04%) ▼|FDX309.76-3.12 (-1.00%) ▼|GD374.31-0.33 (-0.09%) ▼|GE356.03-10.95 (-2.98%) ▼|GEV1,070.99-6.09 (-0.57%) ▼|GILD135.82-0.54 (-0.40%) ▼|GM76.24+0.21 (+0.28%) ▲|GOOG358.71-4.91 (-1.35%) ▼|GOOGL361.92-5.11 (-1.39%) ▼|GS1,029.64-13.34 (-1.28%) ▼|HD336.21-9.00 (-2.61%) ▼|HON220.36-4.69 (-2.08%) ▼|IBM302.05-4.08 (-1.33%) ▼|INTC110.24-0.15 (-0.14%) ▼|INTU272.10-9.07 (-3.23%) ▼|ISRG415.10-12.20 (-2.86%) ▼|JNJ263.40-3.84 (-1.44%) ▼|JPM330.62-8.60 (-2.54%) ▼|KO83.40-0.65 (-0.77%) ▼|LIN527.67-10.56 (-1.96%) ▼|LLY1,215.83-19.73 (-1.60%) ▼|LMT527.96-7.42 (-1.39%) ▼|LOW212.85-8.05 (-3.64%) ▼|LRCX333.15+7.02 (+2.15%) ▲|MA519.86-11.76 (-2.21%) ▼|MCD278.25-3.96 (-1.40%) ▼|MDLZ59.48-0.74 (-1.23%) ▼|MDT82.01-1.82 (-2.17%) ▼|META603.12-12.46 (-2.02%) ▼|MMM154.70-3.31 (-2.09%) ▼|MO72.81-0.15 (-0.21%) ▼|MRK125.99-2.87 (-2.23%) ▼|MS218.07-3.97 (-1.79%) ▼|MSFT383.34-5.50 (-1.41%) ▼|MU948.80+10.42 (+1.11%) ▲|NEE87.44-1.03 (-1.16%) ▼|NFLX75.59-0.59 (-0.77%) ▼|NKE42.89-0.32 (-0.74%) ▼|NOW107.78-2.95 (-2.66%) ▼|NVDA204.12+7.19 (+3.65%) ▲|ORCL140.49-1.11 (-0.78%) ▼|PEP142.51-2.47 (-1.70%) ▼|PFE24.05-0.02 (-0.08%) ▼|PG148.40-4.35 (-2.85%) ▼|PLTR132.22-2.15 (-1.60%) ▼|PM187.07-0.72 (-0.38%) ▼|QCOM186.56+3.59 (+1.96%) ▲|RTX194.91-5.94 (-2.96%) ▼|SBUX103.87+0.26 (+0.25%) ▲|SCHW101.70-0.23 (-0.23%) ▼|SO96.38-0.91 (-0.94%) ▼|SPG219.09-8.10 (-3.57%) ▼|T21.12+0.03 (+0.14%) ▲|TMO510.13-6.49 (-1.26%) ▼|TMUS180.14-4.59 (-2.48%) ▼|TSLA394.06-8.84 (-2.19%) ▼|TXN301.32+8.02 (+2.73%) ▲|UBER73.60-0.73 (-0.98%) ▼|UNH425.60-2.59 (-0.60%) ▼|UNP280.94-2.18 (-0.77%) ▼|UPS109.94-2.02 (-1.80%) ▼|USB61.00-1.89 (-3.01%) ▼|V347.53-4.67 (-1.33%) ▼|VZ42.45-0.14 (-0.33%) ▼|WFC85.56-1.62 (-1.86%) ▼|WMT113.10+1.56 (+1.40%) ▲|XOM141.13-0.56 (-0.40%) ▼|
22.2 C
New York
Thursday, July 9, 2026

Tag: research

newssourceFORcompanyinformationcontent1releasesmarket

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

BexBack Launches $50 Welcome Bonus and 100% Deposit Match to Empower Crypto Traders with 100x Leverage

SINGAPORE, June 21, 2025 (GLOBE NEWSWIRE) -- BexBack Exchange has launched an aggressive new promotion to empower both new and seasoned crypto traders: a $50 welcome bonus and a 100% deposit match for all new users. As the crypto market braces for another period of high volatility, BexBack is making futures trading more accessible and profitable than ever. With up to 100x leverage, zero KYC requirements, and support for over 50 digital assets, the platform provides an ideal environment for those seeking to capitalize on market swings without large upfront capital.

Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The...

The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults...

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA’s 85th Scientific Session

CAMBRIDGE, Mass., June 21, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

ATN Night Vision Scopes Revolutionize Late-Night Hog Hunting for Serious Hunters

DORAL, Fla., June 21, 2025 (GLOBE NEWSWIRE) -- Wild hog hunting after dark presents a unique challenge even for the most seasoned sportsmen. Nocturnal and highly elusive, feral hogs demand precision, stealth, and top-tier equipment. That’s why hunters nationwide are turning to ATN, a global leader in digital and thermal optics, to gain the upper hand during late-night hunts.

Bitcoin Solaris Announces Final Presale Phase Ahead of July Launch

Bitcoin Solaris

TALLINN, Estonia, June 21, 2025 (GLOBE NEWSWIRE) -- Bitcoin Solaris (BTC-S), a next-generation blockchain project, has officially entered the final stages of its highly anticipated presale. With its public launch set for July 31, 2025, the momentum around BTC-S is building rapidly as thousands of users secure early access to what many are calling one of the most accessible and performance-driven blockchain ecosystems of the year.

BTC-S: Where Scalability Meets Accessibility

IIM Udaipur Concludes Executive Education Training Program for PM SHRI School Principals in Collaboration with RSSP Jaipur

UDAIPUR, India, June 21, 2025 /PRNewswire/ -- Indian Institute of Management Udaipur (IIM Udaipur), in collaboration with the Rajasthan School Shiksha Parishad (RSSP), Jaipur,...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsResearch

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers